Form 4: Supernus Pharmaceuticals Executive Tami Tillotson Martin Reports Stock Transactions

Tami Tillotson Martin, a Senior VP at Supernus Pharmaceuticals, reported the acquisition of 1,250 shares of common stock and the disposal of 485 shares to cover tax obligations.

Summary

• On February 23, 2024, Tami Tillotson Martin, a Senior Vice President at Supernus Pharmaceuticals, acquired 1,250 shares of common stock.
• These shares were obtained through the vesting of restricted stock units (RSUs).
• On the same day, 485 shares were disposed of to satisfy tax withholding requirements related to the RSU vesting at a price of $29.06 per share.
• Following these transactions, Martin directly owns 86,933 shares of Supernus Pharmaceuticals common stock.
• Martin also holds 3,750 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing reflects routine stock transactions related to executive compensation. There are no indications of unusual or concerning activity.

Positives

• The acquisition of shares through RSU vesting indicates a form of compensation and alignment of the executive's interests with the company's performance.

Negatives

• The disposal of shares to cover tax obligations reduces the executive's holdings, although this is a common practice.

Future Outlook

The restricted stock units vest in four equal annual installments, beginning on February 23, 2024, suggesting future stock acquisitions by the reporting person.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates